Status:
COMPLETED
PraxbindTM India PMS Program
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Thromboembolism
Eligibility:
All Genders
Brief Summary
This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availabili...
Eligibility Criteria
Inclusion
- \- Patients treated with Pradaxa (dabigatran etexilate) capsules with requirement of rapid reversal of the anticoagulant effects of dabigatran: For emergency surgery/urgent procedures (or) In life-threatening or uncontrolled bleeding
- \- Written informed consent in accordance with International Conference on Harmonization Good Clinical Practice (GCP) guidelines and local legislation and/or regulations
Exclusion
- Participation in a PraxbindTM clinical trial
Key Trial Info
Start Date :
December 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03359889
Start Date
December 26 2018
End Date
January 13 2020
Last Update
August 25 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mazumdar Shaw Medical centre
Bangalore, India, 560099
2
Columbia Asia Referral Hospital
Bengaluru, India, 560055
3
Care Hospital
Hyderabad, India, 500034